Biogen - BIIB Stock Forecast, Price & News

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Trading Down 0.6 %

NASDAQ:BIIB opened at $216.34 on Friday. The company has a market capitalization of $31.39 billion, a PE ratio of 15.43, a P/E/G ratio of 1.01 and a beta of 0.40. The company has a fifty day moving average of $211.27 and a 200 day moving average of $209.03. Biogen has a 1 year low of $187.16 and a 1 year high of $350.45. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.94 and a quick ratio of 1.68.

Biogen (NASDAQ:BIIB - Get Rating) last posted its earnings results on Wednesday, July 20th. The biotechnology company reported $5.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.09 by $1.16. Biogen had a net margin of 19.36% and a return on equity of 22.36%. The company had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.48 billion. During the same period in the previous year, the firm posted $5.68 earnings per share. The firm's quarterly revenue was down 6.7% on a year-over-year basis. Research analysts forecast that Biogen will post 16.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BIIB. Royal Bank of Canada decreased their price target on shares of Biogen from $264.00 to $259.00 in a research note on Wednesday, July 20th. Robert W. Baird restated a "neutral" rating and issued a $224.00 price objective on shares of Biogen in a report on Tuesday, August 2nd. StockNews.com upgraded shares of Biogen from a "buy" rating to a "strong-buy" rating in a report on Wednesday, July 27th. SVB Leerink cut their target price on shares of Biogen from $300.00 to $270.00 and set an "outperform" rating on the stock in a research report on Thursday, April 21st. Finally, Wedbush reiterated a "neutral" rating on shares of Biogen in a research note on Thursday, April 28th. Thirteen investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $257.36.